2026-07-15 Eisai Co.,Ltd. “The results of the "Rekenbi®" real-world clinical LEADER study were presented at AAIC 2026—among patients with early-stage Alzheimer's disease who received treatment for an average of 17 months, over 75% maintained their disease stage and approximately 7% showed improvement—these real-world clinical data support the long-term benefits of continued administration of "Rekenbi" and provide important insights into the actual treatment practices in daily clinical practice.”